Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

Summary

RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of Covid-19 patients with defined hyperinflammation.

Timeline

Start

2020-04-22

Primary completion

2021-07-15

Completion

2021-07-15

Outcome

Met primary endpoint

paper On day 7, median CIS declined to 6 (range, 1-13); 71% of patients (CI 64-77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. PMID 37507425 ↗

Publications

• Hammersen J, Birndt S, Dohner K, Reuken P, Stallmach A, Sauerbrey P, La Rosee F, Pfirrmann M, Fabisch C, Weiss M, Trager K, Bremer H, Russo S, Illerhaus G, Dromann D, Schneider S, La Rosee P, Hochhaus A. The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial. Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28.
• La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, La Rosee P. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0. Epub 2020 Jun 9.

Drugs

Indications